DeepMed Research

Ibritumomab tiuxetan

Generic Name: Ibritumomab tiuxetan

Brand Names: Zevalin

Drug Type: Biotech

CAS Number: 206181-63-7

Unique Ingredient Identifier: 4Q52C550XK

Background: Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.

Indication: For treatment of non-Hodgkin's lymphoma

Associated Conditions: Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed follicular B-cell non-Hodgkin's lymphoma

Clinical Trials

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Phase 3

Completed

Conditions: Follicular Non-Hodgkin's Lymphoma

Interventions: Drug: R-CHOP or R-bendamustine
Drug: Standard Maintenance
Drug: Maintenance weekly x4
Drug: Ibritumomab Tiuxetan + Maintenance
Drug: Observation

First Posted Date: 2014-02-14

Last Posted Date: 2022-06-21

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 807

Registration Number: NCT02063685

Locations: 🇮🇹
Irccs Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹
Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Sede Di Meldola (Fc), Meldola, Forlì Cesena, Italy
🇮🇹
Fondazione IRCCS Milano INT, Milano, MI, Italy

and more 45 locations

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Phase 3

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: Zevalin
Drug: Rituximab

First Posted Date: 2012-08-10

Last Posted Date: 2021-10-04

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 1

Registration Number: NCT01662102

Locations: 🇺🇸
Charleston Area Medical Center, Charleston, West Virginia, United States
🇺🇸
Park Nicollet Institute, Saint Louis Park, Minnesota, United States
🇺🇸
Northeast Georgia Cancer Care, Athens, Georgia, United States

and more 2 locations

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Y Zevalin
Drug: In Zevalin
Drug: Rituxan
Drug: BCNU
Drug: VP -16
Drug: Ara-C
Drug: Melphalan
Procedure: Stem Cell Infusion
Drug: G-CSF

First Posted Date: 2012-02-24

Last Posted Date: 2014-09-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01538472

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Phase 3

Terminated

Conditions: Diffuse Large B-cell Lymphoma
Follicle Center Lymphoma

Interventions: Drug: Zevalin
Drug: Y-90-Zevalin
Drug: Rituximab
Drug: In-111 Zevalin

First Posted Date: 2012-01-13

Last Posted Date: 2021-12-16

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 79

Registration Number: NCT01510184

Locations: 🇺🇸
Hackensack UMC / John Theurer Cancer Center, Hackensack, New Jersey, United States
🇫🇷
CHU Dupuytren, Limoges, Cedex, France
🇮🇱
Chaim Sheba Medical Center, Tel-Hashomer, Israel

and more 90 locations

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

Phase 2

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: 90Y Ibritumomab tiuxetan
Drug: Rituximab

First Posted Date: 2011-12-16

Last Posted Date: 2019-10-15

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 76

Registration Number: NCT01493479

Locations: 🇫🇷
Centre Hospitalier Universitaire de Lille, Lille, France
🇫🇷
Centre Hospitalier Universitaire de Nantes, Nantes, France
🇫🇷
Centre Henri Becquerel, Rouen, France

and more 4 locations

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: Rituximab
Drug: 111In Ibritumomab
Procedure: Planar Scintigraphy Imaging
Drug: 90Y IbritumomabTiuxetan
Drug: Fludarabine
Drug: Bendamustine
Drug: Thymoglobulin
Drug: Tacrolimus
Drug: Methotrexate
Drug: Mycophenolate
Drug: G-CSF
Procedure: Stem Cell Transplantation

First Posted Date: 2011-12-13

Last Posted Date: 2020-05-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01490723

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: indium-111-ibritumomab tiuxetan
Drug: 90Y Zevalin

First Posted Date: 2010-09-23

Last Posted Date: 2017-03-20

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 8

Registration Number: NCT01207765

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: ibritumomab tiuxetan (Zevalin)

First Posted Date: 2010-07-08

Last Posted Date: 2010-07-08

Lead Sponsor: Chonnam National University Hospital

Target Recruit Count: 20

Registration Number: NCT01157988

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy

Phase 2

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: FM+R
Drug: Zevalin (Ibritumomab Tiuxetan)

First Posted Date: 2009-03-10

Last Posted Date: 2009-03-12

Lead Sponsor: University of Bologna

Target Recruit Count: 55

Registration Number: NCT00859001

Locations: 🇮🇹
Istituto di Ematologia e Oncologia Medica Seràgnoli, Bologna, BO, Italy

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: CHOP21-R
Drug: Zevalin

First Posted Date: 2009-02-25

Last Posted Date: 2009-02-25

Lead Sponsor: University of Bologna

Target Recruit Count: 55

Registration Number: NCT00850512

Locations: 🇮🇹
Istituto di Ematologia e Oncologia Medica Seràgnoli, Bologna, BO, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy